67 results about "Tissue level" patented technology

Methods and systems for selecting tachyarrhythmia therapy based on the morphological organization level of the arrhythmia are described. Morphological organization levels of arrhythmias are associated with cardiac therapies. The morphological organization levels are related to cardiac signal morphologies of the arrhythmias. An arrhythmia episode is detected and the morphological organization level of the arrhythmia episode is determined. A cardiac therapy associated with the morphological organization level of the arrhythmia episode is delivered to treat the arrhythmia. For example, the morphological organization levels may be associated with the cardiac therapies based on one or more of retrospective database analysis patient therapy tolerance, and physician input. The associations may be static or may be dynamically adjusted based on therapy efficacy.

Three-dimensional tissue-like organization of cells by high cell-seeding-density culture termed as macromass culture is described. By macromass culture, cells can be made to organize themselves into a tissue-like form without the aid of a scaffold and three-dimensional macroscopic tissue-like constructs can be made wholly from cells. Tissue-like organization and macroscopic tissue-like constructs can be generated from fibroblastic cells of mesenchymal origin (at least), which can be either differentiated cells or multipotent adult stem cells. In this work, tissue-like organization and macroscopic tissue-like constructs have been generated from dermal fibroblasts, adipose stromal cells-derived osteogenic cells, chondrocytes, and from osteoblasts. The factor causing macroscopic tissue formation is large scale culture at high cell seeding density per unit area or three-dimensional space, that is, macromass culture done on a large scale. No scaffold or extraneous matrix is used for tissue generation, the tissues are of completely cellular origin. No other agents (except high cell-seeding-density) that aid in tissue formation such as tissue-inducing chemicals, tissue-inducing growth factors, substratum with special properties, rotational culture, etc, are employed for tissue formation. These tissue-like masses have the potential for use as tissue replacements in the human body. Tissue-like organization by high cell-seeding-density macromass culture can also be generated at the microscopic level.

A system and method for confocal imaging of tissue in vivo and in situ, e.g., for minimally invasive diagnosis of patients. A catheter is provided that has a dye carrier coupled to the distal end of a fiber optics bundle, which allows for the introduction of at least one fluorescent dye therein the dye carrier into a portion of the tissue of interest of a subject or patient when the dye carrier is selectively brought into contact with the portion of the tissue of interest. The resulting confocal images permit the acquisition of diagnostic information on the progression of diseases at cellular / tissue level in patients. Furthermore, a system for ECG-triggered image acquisition is provided.

A computer implemented method of generating at least one shape of a region of interest in a digital image is provided. The method includes obtaining, by an image processing engine, access to a digital tissue image of a biological sample; tiling, by the image processing engine, the digital tissue image into a collection of image patches; obtaining, by the image processing engine, a plurality of features from each patch in the collection of image patches, the plurality of features defining a patch feature vector in a multidimensional feature space including the plurality of features as dimensions; determining, by the image processing engine, a user selection of a user selected subset of patches in the collection of image patches; classifying, by applying a trained classifier to patch vectors of other patches in the collection of patches, the other patches as belonging or not belonging to a same class of interest as the user selected subset of patches; and identifying one or more regions of interest based at least in part on the results of the classifying.

The invention relates to a live body fluorescent endoscopic spectrum imaging device, comprising a light source unit, a light split unit, a scanning light guide unit, a fiber bundle endoscopic unit, an electrooptical signal detection and acquisition unit and a computer, wherein the light source unit consists of a collimating unit and a band filter. The imaging device is characterized in that the light of the collimating unit passes through the band filter and then enters the light split unit, the light split unit is provided with two paths of interfaces, one path of the interfaces of the light split unit is connected with the scanning light guide unit, the scanning light guide unit is connected with the fiber bundle endoscopic unit, and the other path of the interfaces of the light split unit is connected with the electrooptical signal detection and acquisition unit which is connected with the computer. The imaging device has the characteristics that: 1, a Fourier transform spectrometer is used to detect a sample excitation spectrum, and has the advantages of high spectral resolution (1nm), adjustable spectral resolution and the like; and 2, the fluorescent live body endoscopic spectrum imaging system can provide not only imaging diagnosis at tissue level but also spectrum diagnosis at molecular level.

The invention relates to a group of anti-human CD146 molecules which are developed by utilizing the biological technology and an established high-sensitive sandwich ELISA method for detecting the solubility CD146. The invention includes anti-human CD146 mouse monoclonal antibodies of AA1, AA2, AA3, AA4, AA5 and AA7, and the method of utilizing the combination of the antibodies and the sandwich ELISA specificity for detecting the solubility CD146. The group of antibodies can identify the human source CD146 on the molecular, the cellular and the tissue levels, which can be divided into two categories based on the identified different epitopes. The sandwich ELISA method which is combined by the antibody AA1 and another strain of anti-human CD146 mouse monoclonal antibody AA98 can detect the solubility CD146 at each milliliter nano-gram level. The antibodies and the detection means can become the effective detection or diagnosis tools and method in the basic research or the clinical application and provide good carriers for the targeted therapy of the CD146-related diseases at the same time.

A dental implant assembly is provided, as well as a system and method for exposing an embedded implant after osseointegration has taken place. The implant assembly comprises an implant member for embedding in the jaw and a rest factor member for securing to the implant member, the rest factor member having an upper rest surface just above the tissue level for opposing an overlying portion of a prosthesis anchored elsewhere in the jaw to form a non-retentive rest or support for accepting down pressure from the prosthesis. The implant member is relatively short and can be installed in distal jaw regions without interference with the mandibular nerve. A bore is cut out in the jaw for receiving the implant, inserting the implant and an attached healing screw in the implant. The implant site is closed and osseointegration takes place over an extended period. Subsequently, the implant site is uncovered, the healing screw is removed, and the rest factor member is secured in the implant.

Physiologic sensors and methods of application are described. These sensors function by detecting recently discovered variations in the spectral optical density at two or more wavelengths of light diffused through the skin. These variations in spectral optical density have been found to consistently and uniquely relate to changes in the availability of oxygen in the skin tissue, relative to the skin tissue's current need for oxygen, which we have termed Physiology Index (PI). Current use of blood gas analysis and pulse oximetry provides physiologic insight only to blood oxygen content and cannot detect the status of energy conversion metabolism at the tissue level. By contrast, the PI signal uniquely portrays when the skin tissue is receiving ‘less than enough oxygen,’‘just the right amount of oxygen,’ or ‘more than enough oxygen’ to enable aerobic energy conversion metabolism. The PI sensor detects one pattern of photonic response to insufficient skin tissue oxygen, or tissue hypoxia, (producing negative PI values) and a directly opposite photonic response to excess tissue oxygen, or tissue hyperoxia, (producing positive PI values), with a neutral zone in between (centered at PI zero). Additionally, unique patterns of PI signal response have been observed relative to the level of physical exertion, typically with a secondary positive-going response trend in the PI values that appears to correspond with increasing fatigue. The PI sensor illuminates the skin with alternating pulses of selected wavelengths of red and infrared LED light, then detects the respective amount of light that has diffused through the skin to an aperture located a lateral distance from the light source aperture. Additional structural features include means of internally excluding light from directly traveling from the light emitters to the photodetector within the sensor. This physiology sensor and methods of use offer continuous, previously unavailable information relating to tissue-level energy conversion metabolism. Several alternative embodiments are described, including those that would be useful in medical care, athletics, and personal health maintenance applications.

The invention discloses an ultrasonic elastography andpressure feedback method based on receive-side spatial-compounding, namely, a medical ultrasonic elastography algorithm realized by an improved algorithm based on phase zero. When calculating displacement, the traditional algorithm carries out displacement calculation on a scanning line, which leads to large errors in the case that tissue movement contains a horizontal component; while, the window of noval algorithm covers a plurality of adjacent scanning lines, thereby reducing the errors brought by the horizontal component of tissue movement and improving the signal-to-noise ratio of the ultrasonic elastography. At the same time, the method provided in the invention also employs Receive-Side Spatial-Compounding technology in an elastography system, thereby further reducing the impact of elastography noise and further advancing the signal-to-noise ratio of the system. Finally, an average-strain-based elastography pressure feedback technology is provided to prompt current pressing strength and a normal pressing range for a doctor.

The present invention relates to a group of anti-human CD146 molecules developed by using a biological technology and an established high sensitivity sandwich ELISA method for soluble CD146 detection. The present invention provides anti-human CD146 mouse monoclonal antibodies (AA1, AA2, AA3, AA4, AA5 and AA7), and a method for specially detecting soluble CD146 by using antibody combinations and sandwich ELISA, wherein the antibodies can specifically recognize human source CD146 at a molecular level, a cellular level and a tissue level, and can be divided into two classes based on recognition of different epitopes. With an antibody AA1 and anti-human CD146 mouse monoclonal antibody AA98 combined sandwich ELISA method, nanogram-scale soluble CD146 in per ml of the solution can be detected. The antibodies and the detection method can become effective detection or diagnosis tools and methods in basic researches or clinical applications, and can further provide good carriers for targeted therapies of CD146-related diseases.

The invention relates to an anti-tumor drug screening kit based on a three-dimensional micro-tissue level and an application method thereof. The anti-tumor drug screening kit comprises a three-dimensional cell culture material, a tissue cell dispersion reagent, a proteinase inhibitor, a basic cell culture medium, blood serum, antibiotics, a balance salt solution, a cell activity detection reagentand a cell filter screen. The application method comprises the following steps: dispersing tumor tissues of a patient to obtain tissue blocks, tissue fragments, cell aggregates and / or dispersed singlecells; then culturing the dispersed tumor tissues of the patient and a cell sample through a three-dimensional culture method and enabling the cells to grow in a three-dimensional space to form a spherical structure or an irregular three-dimensional structure with a stereoscopic shape; finally, carrying out a drug sensitivity test on tumor micro-tissues obtained by three-dimensional culture. Theanti-tumor drug screening kit based on the three-dimensional micro-tissue level is simple to operate and is suitable for the drug sensitivity tests of various solid tumors.

The invention belongs to the field of medicine, which relates to Deferiprone and a novel medicated purpose of a Deferiprone preparation, in particular to Deferiprone (1,2- dimethyl-3-hydroxide radical-4-pyridine, Deferiprone) and the application of the Deferiprone preparation in the prevention and curing of Anthracycline medicine heart toxicity. The invention researches the preventing and curing function of the Deferiprone to bandicoot heart toxicity caused by Adriamycin from the cell level, the tissue level and the whole level and prepares biodegradable type Deferiprone implant, Deferiprone troche, capsule, oral liquor and injection that can release medicine continuously. An experimental result proves that the Deferiprone and the Deferiprone preparation can not only improves the cardiac muscle shrinkage functions and protects the myocardial cell organ structure, but also complexes free iron ions directly, reduces the heart toxicity and other side and toxic effects caused by the Anthracycline medicine obviously and the mortality rate caused by the Anthracycline medicine.

The use of phthalocyanines together with a free radical source for photodynamic therapy is described. The free radical sources cause the photodecomposition of the phthalocyanines, which can be useful for various reasons such as allowing light to penetrate to lower tissue levels that would otherwise be obscured. The nature of the phthalocyanine and the free radical source chosen can both have an influence on the rate of photodecomposition. The free radical sources can be provided along with the phthalocyanines either in free unattached form, or they can be attached to the phthalocyanines themselves.

This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. There orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthrracyclines.

The invention provides an immumofluorescent antibody labeling method of a cotton tender tissue microtube framework. The method comprises the following process steps: performing fixation by a fixing liquid; performing dehydration; freezing a microtome section; removing non-specific fluorescence; and performing immunolabelling; performing section sealing and the like. The method provided by the invention combines fluorescein with the microtube framework at the cotton tender tissue to immunolabel the cotton tender tissue microtube framework so as to observe changes of the cotton tender tissue microtube framework in the tissue level and research resistance of cottons to non-biological adversity stress and resistance of cottons on plant diseases and insect pests. The method provided by the invention is simple in step, easy to master, clear in result and suitable for observing the cotton tender tissue microtube framework, and also has certain reference value in observing other plant tender tissue microtube frameworks.

This invention is in the field of chemical restructuring of pharmaceutical agents known to cause tissue toxicity as a side effect, by producing their orotate derivatives. More particularly, it concerns orotate derivatives of the anthracyclines, doxorubicin and daunorubicin, that are found to reduce levels of the pharmaceutical agent in noncancerous tissues. There orotate derivatives are equally efficacious in inhibiting the SCCAKI-1 kidney tumor in animals and the reduction in the heart tissue of doxorubicin compared with doxorubicin HCl suggests a reduction in toxicity induced by free radical generation by the anthrracyclines.

The invention discloses a tissue ablation method and equipment. The device includes a plurality of RF ablation electrodes, and a plurality of sensor elements, each movable in tissue to be ablated from a retracted to a deployed position. A control device in the device is operatively connected to the electrodes for supplying RF power to the electrodes to produce tissue ablation proceeding from the individual electrode ablation zones to fill a combined electrode ablation volume. The control means is operatively connected to the sensor element for determining the degree of ablation in the region of the sensor element. The supply of RF power to the electrodes can thus be adjusted to control the level and extent of tissue ablation throughout the combined electrode volume. The electrodes are preferably hollow needle electrodes through which fluid can be injected into the tissue and, under the control of the control unit, the tissue ablation is modulated and optimized.

The present invention establishes a new standard for investigative studies of patient-specific, genetic cardiac diseases at a functional, tissue level by creating a novel platform for the study of cardiac related diseases, including cardiac conduction dysfunction, arrhythmias and depressed contractility for example. Provided herein are novel compositions of human engineered heart slices (EHS) formed from thin slices of decellularized cardiac tissue. Also included are compositions comprising a hybrid of decellularized tissue and organotypic organ slice technology. Intact mammalian hearts are precision cut to obtain thin slices in a range of thicknesses, decellularized, and seeded with various mammalian cells which can be from a variety of sources. Methods of investigation of many diseases and methods of use of these compositions for screening compounds for therapeutic purposes are also provided.

Disclosed is a computer implemented method for fully automated tissue diagnosis that trains a region of interest (ROI) classifier in a supervised manner, wherein labels are given only at a tissue level, the training using a multiple-instance learning variant of backpropagation, and trains a tissue classifier that uses the output of the ROI classifier. For a given tissue, the method finds ROIs, extracts feature vectors in each ROI, applies the ROI classifier to each feature vector thereby obtaining a set of probabilities, provides the probabilities to the tissue classifier and outputs a final diagnosis for the whole tissue.

The invention discloses a noninvasive skin wound sampling observation and analysis method. Exfoliative cells of wound tissues of a patient are glued by using a glass slide, are fixed and dyed and a patch is analyzed. The observation and analysis method is simple in implement process, convenient to operate, free of special instrument or equipment, convenient and safe to use, and convenient to popularize in a primary medical network. Meanwhile, the observation and analysis method is scientific and advanced; observation of the curative effect on a patient in the treatment process from the tissue level, the cell level and the molecular level can be achieved by using a simple operation; and healing of the wound is objectively and scientifically recorded and judged. The difference in doctors in the cognitive level is avoided and teaching instruction for medical students is also facilitated; system recording of cases in the treatment process can be achieved, comparison and analysis of different cases are facilitated; evaluation of the curative effect of a new drug is also facilitated; and these advantages are not clinically available today.

The invention provides a novel coronavirus intestinal infection model construction method based on a micro-fluidic organ chip, and particularly aims at simulating and constructing a series of intestinal tissue pathophysiological changes such as intestinal barrier integrity damage, mucus secretion abnormity and intestinal immune response activation occurring after novel coronavirus infection. The micro-fluidic chip is mainly composed of two layers of micro-channels, the channels are separated by a polydimethylsiloxane wedge-shaped porous membrane, each layer of channel is provided with an inlet and an outlet, and a static or dynamic environment can be formed through fluid. By respectively inoculating intestinal epithelial cells and endothelial cells into the upper channel and the lower channel on the chip and introducing circulating immune cells into the lower channel after virus infection, the miniature intestinal tissue on the chip is formed. Novel coronavirus particles are added into an upper channel of the chip, so that novel coronavirus exposure of intestinal tissues is simulated. The invention provides a multi-factor participated tissue level research system for the research of the SARS-CoV-2 infected intestinal pathogenesis.

The invention relates to a urinary cytology artificial intelligence urinary tract epithelium cancer identification system. The system includes: a data classification module used for classifying urinary cytology data acquired in advance to obtain a urinary cytology positive data set and a urinary cytology negative data set, and matching the urinary cytology positive data set and the urinary cytology negative data set based on an operation pathology result to obtain a true positive data set, a false positive data set, a true negative data set and a false negative data set; a data grouping module which is used for grouping various data sets obtained by the data classification module to obtain a training-verification set and a test set; a model training module which is used for training a pre-constructed model to obtain a final model; a model testing and auditing module which is used for performing cell level testing and tissue level testing on the obtained final model; and an identification module which is used for identifying the to-be-identified urinary cytology data to obtain an identification result. The system can be widely applied to the field of cytology pathology recognition.

The present invention is directed to a method of inducing tolerance to self-antigens in a subject having an autoimmune diseases. In particular, the invention provides a pharmaceutical composition and method of use thereof for the modulation of immunogical activity in an animal subject. Said modulation may be an increased tolerance to self apoptotic cells, a reduction in the tissue levels of autoantibodies associated with apoptotic cells, a reduction in the tissue levels of autoantibodies associated with an autoimmune disease, a reduction in the level of inflammation and inflammatory mediators associated with an autoimmune disease, a reduction in the level of tissue damage associated with an autoimmune disease, or a combination thereof.

The invention provides application of a pH-responsive copper-based compound nanomaterial serving as a disulfiram carrier in preparation of a multi-level selective tumor treatment medicine. According to the invention, a functional carrier for performing copper doping (Cu-MSNs) in mesoporous silicon dioxide nanoparticles is prepared by adopting a metal ion doping template method, and a nanodrug delivery system is obtained after disulfiram is loaded. The nanodrug delivery system prepared by the invention can release copper ions and disulfiram after being enriched at a tumor site through an EPR effect, plays a role in both a tissue level and a cell level, improves the effect of chemotherapeutic drugs, reduces systemic toxic and side effects caused by a traditional drug delivery route, and provides a new research direction for in-situ local treatment of tumors.

The invention relates to a method for co-culturing pluripotent stem cell-derived human liver and pancreas islet based on multiple organ chips. The multi-organ culture chip can be composed of two or more cell culture chambers, the bottom of each culture chamber is provided with a micro-pit (column)-shaped structure arranged in an array mode so that three-dimensional growth of cells can be facilitated, the cell culture chambers are connected in series through a plurality of channels which are not limited in length and micron in width, and a closed continuous perfusion culture system is achieved through a peristaltic pump. Liver and pancreas islet for co-culture are human-derived liver-like and pancreas islet-like at a three-dimensional tissue level induced by pluripotent stem cells and have partial physiological functions of the liver and pancreas islet through gene, protein and secretion level identification, and in the same system, pancreas islet cells and liver cells are mutually promoted through secreted cell factors, co-culture of the pancreas islet and the liver for a long time in vitro and glucose homeostasis regulation closer to a physiological level are realized.

The invention relates to a simulation system for simulating a fracture healing process and belongs to the biomedical engineering field. The invention aims to predict the complex process of fracture healing and explore an optimal fracture healing plan. The system includes a fracture region analysis model building module, a blood supply reconstruction subsystem, a fracture healing process modeling subsystem and a program termination judgment module; the fracture region analysis model building module is used for establishing a fracture region geometric model and a finite element model; the bloodsupply reconstruction subsystem is used for modeling the regenerative process of blood vessels from an intracellular molecular level and a cellular level; the fracture healing process modeling subsystem is used for modeling the fracture healing process from a tissue level; and the program termination judgment module is used for judging whether a program is terminated. According to the simulation system for simulating the fracture healing process of the invention, the fracture healing process is modeled from the intracellular molecular level, the cellular level and the tissue level, and therefore, the modeling of the fracture healing process can be improved, the fracture healing process can be simulated more accurately, and favorable help can be provided for the exploration of an optimal fracture healing treatment plan.